U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131345) titled 'Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma' on June 14.
Brief Summary: This clinical trial aims to investigate the effectiveness and safety of a new treatment combination-Iparomlimab and Tuvonralimab (QL1706, a dual-function antibody targeting PD-1 and CTLA-4) combined with chemotherapy-for patients with malignant mesothelioma (MM). MM is a rare and aggressive cancer often linked to asbestos exposure. Current treatments have limited success, and this study seeks to explore a potentially more effective and safer option.
Study Design:
Phase Ib (Safety Phase): 6 patients will receive the combina...